JNGHF — Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR

OTC · Unknown · Unknown · CIK 2071868 · China
Last close
$7.22
Market Cap
52W High
$7.80
52W Low
$7.07
ADV30
842
Next earnings
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.
No quarterly fundamentals indexed for this ticker.

Yahoo Snapshot (yfinance, live)

Total Revenue
$32,564,369,408
EBITDA
$9,452,852,224
Free Cash Flow
$6,307,738,624
Enterprise Value
$8,417,134,592
Total Cash
$40,635,797,504
Total Debt
$67,474,744
Shares Out
Trailing EPS
Book Value
$1.40
ROE
14.5%
ROA
8.8%
Div Yield

Peers — same industry

TickerNameMarket CapLastDaily %
SPY SPDR S&P 500 ETF TRUST $669.49B $729.46
QQQ INVESCO QQQ TRUST, SERIES 1 $260.13B $661.73
KLAC KLA CORP $222.31B $170.19
TMO THERMO FISHER SCIENTIFIC INC. $214.22B $576.46
IBM INTERNATIONAL BUSINESS MACHINES CORP $213.34B $226.44

News headlines (Yahoo Finance, 1h cache)

China’s rapid rise in drug development casts a long shadow over US oncology
2026-07-24 15:26 · Yahoo
IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs
2026-07-17 13:00 · Yahoo
Kailera Therapeutics (KLRA) is One of the Best IPO Stocks with Huge Upside Potential
2026-07-10 13:58 · Yahoo
Eli Lilly's Market Cap Balloons Again On This IPO's Setback
2026-07-07 20:09 · Yahoo
Update: Kailera Says Oral Small Molecule KAI-7535 Achieves Up to 11% Weight Loss in Phase 3 Trial; Shares Fall
2026-07-07 18:49 · Yahoo
Kailera points to Phase III oral obesity drug data as it tees up Foundayo rivalry
2026-07-07 14:59 · Yahoo
Kailera Says Oral Small Molecule KAI-7535 Achieves Up to 11% Weight Loss in Phase 3 Trial
2026-07-07 12:08 · Yahoo
Kailera says obesity pill succeeds in late-stage trial in China
2026-07-07 11:59 · Yahoo
Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535
2026-07-07 11:00 · Yahoo
Hengrui’s Heng Yi® Approved in China as an Innovative Cyclosporine Ophthalmic Solution for the Treatment of Dry Eye Disease
2026-06-30 05:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.